These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 25159072)

  • 1. Emerging biology of PDE10A.
    Wilson LS; Brandon NJ
    Curr Pharm Des; 2015; 21(3):378-88. PubMed ID: 25159072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 1: Overview of the Chemical and Biological Research.
    Jankowska A; Świerczek A; Wyska E; Gawalska A; Bucki A; Pawłowski M; Chłoń-Rzepa G
    Curr Drug Targets; 2019; 20(1):122-143. PubMed ID: 30091414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PDE10A inhibitors: novel therapeutic drugs for schizophrenia.
    Kehler J; Nielsen J
    Curr Pharm Des; 2011; 17(2):137-50. PubMed ID: 21355834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Understanding of PDE10A in the Modulation of Basal Ganglia Circuitry.
    Schülke JP; Brandon NJ
    Adv Neurobiol; 2017; 17():15-43. PubMed ID: 28956328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphodiesterase 10 inhibitors: new disease modifying drugs for Parkinson's disease?
    García AM; Redondo M; Martinez A; Gil C
    Curr Med Chem; 2014 Apr; 21(10):1171-87. PubMed ID: 24372206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoproteomics demonstrates target engagement and exquisite selectivity of the clinical phosphodiesterase 10A inhibitor MP-10 in its native environment.
    Schülke JP; McAllister LA; Geoghegan KF; Parikh V; Chappie TA; Verhoest PR; Schmidt CJ; Johnson DS; Brandon NJ
    ACS Chem Biol; 2014 Dec; 9(12):2823-32. PubMed ID: 25295858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey.
    Smith SM; Uslaner JM; Cox CD; Huszar SL; Cannon CE; Vardigan JD; Eddins D; Toolan DM; Kandebo M; Yao L; Raheem IT; Schreier JD; Breslin MJ; Coleman PJ; Renger JJ
    Neuropharmacology; 2013 Jan; 64():215-23. PubMed ID: 22750078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington's disease.
    Kleiman RJ; Kimmel LH; Bove SE; Lanz TA; Harms JF; Romegialli A; Miller KS; Willis A; des Etages S; Kuhn M; Schmidt CJ
    J Pharmacol Exp Ther; 2011 Jan; 336(1):64-76. PubMed ID: 20923867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease.
    Giampà C; Laurenti D; Anzilotti S; Bernardi G; Menniti FS; Fusco FR
    PLoS One; 2010 Oct; 5(10):e13417. PubMed ID: 20976216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.
    Cheng J; Grande JP
    Exp Biol Med (Maywood); 2007 Jan; 232(1):38-51. PubMed ID: 17202584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging phosphodiesterase inhibitors for treatment of neurodegenerative diseases.
    Xiang Y; Naik S; Zhao L; Shi J; Ke H
    Med Res Rev; 2024 Jul; 44(4):1404-1445. PubMed ID: 38279990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia.
    Menniti FS; Chappie TA; Humphrey JM; Schmidt CJ
    Curr Opin Investig Drugs; 2007 Jan; 8(1):54-9. PubMed ID: 17263185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations in gene regulation following inhibition of the striatum-enriched phosphodiesterase, PDE10A.
    Strick CA; James LC; Fox CB; Seeger TF; Menniti FS; Schmidt CJ
    Neuropharmacology; 2010 Feb; 58(2):444-51. PubMed ID: 19765598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medicinal chemistry strategies for the development of phosphodiesterase 10A (PDE10A) inhibitors - An update of recent progress.
    Amin HS; Parikh PK; Ghate MD
    Eur J Med Chem; 2021 Mar; 214():113155. PubMed ID: 33581555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphodiesterase 10A in the rat pineal gland: localization, daily and seasonal regulation of expression and influence on signal transduction.
    Spiwoks-Becker I; Wolloscheck T; Rickes O; Kelleher DK; Rohleder N; Weyer V; Spessert R
    Neuroendocrinology; 2011; 94(2):113-23. PubMed ID: 21474921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of Compartmentalised Cyclic Nucleotide Signalling via Local Inhibition of Phosphodiesterase Activity.
    Brescia M; Zaccolo M
    Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27706091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair.
    Knott EP; Assi M; Rao SN; Ghosh M; Pearse DD
    Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28338622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphodiesterases in the CNS: targets for drug development.
    Menniti FS; Faraci WS; Schmidt CJ
    Nat Rev Drug Discov; 2006 Aug; 5(8):660-70. PubMed ID: 16883304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does phosphodiesterase 11A (PDE11A) hold promise as a future therapeutic target?
    Kelly MP
    Curr Pharm Des; 2015; 21(3):389-416. PubMed ID: 25159071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Emerging Role of Phosphodiesterases in Movement Disorders.
    Erro R; Mencacci NE; Bhatia KP
    Mov Disord; 2021 Oct; 36(10):2225-2243. PubMed ID: 34155691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.